Some legal observers theorize that the administration’s unanticipated stance in the case boils down to its unwavering support for executive power, even when it creates odd bedfellows. It doesn’t want its FDA to be hamstrung — including, perhaps, when it gins up its own reason to restrict mifepristone in the future.
Others think it’s a gambit to create cover while it pursues other avenues of restriction, pointing to a suspect “study” published by a right-wing think tank last week.
Read more at Talking Points Memo